Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Qilu Pharmaceutical discloses novel EGFR inhibitors

Nov. 5, 2012

Avastin obtains E.U. approval for recurrent, platinum-sensitive ovarian cancer

Nov. 2, 2012

Results presented from phase II trial of dovitinib in GIST

Nov. 2, 2012

Results presented for randomized phase II study of tivantinib

Nov. 2, 2012

Incyte discloses new PI3Kdelta inhibitors

Nov. 2, 2012

Results from phase III study of masitinib plus Gemzar for pancreatic cancer presented

Nov. 2, 2012

NCI presents phase II data for a cervical cancer vaccine

Oct. 31, 2012

Preliminary phase II data presented for lubrinectedin in ovarian cancer

Oct. 31, 2012

Combination of BKM-120 and irinotecan evaluated in phase I trial

Oct. 31, 2012

Complix receives government grant for Alphabodies development

Oct. 31, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...